Search

The application of various agricultural pesticides can lead to adverse effects on bodily tissues. This study evaluated the impact of dermal exposure to malathion on sex hormone levels and its potential carcinogenicity in mice. 30 adult male mice were randomly assigned to control and treatment groups. The treatment group received a topical application of malathion at 1 ppm (1 ml) for 12 weeks. After the exposure period, serum levels of testosterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) were analyzed, and tissue samples were collected post-necropsy. Cytotoxicity was assessed using the micronucleus assay and MTT method in vitro, and the IC50 value was calculated. Results showed no significant difference in LH levels between groups; however, both testosterone and FSH levels declined significantly in the treated mice. Histological evaluation revealed mild liver toxicity in the treatment group. Additionally, the frequency of micronuclei at various Malathion concentrations was significantly elevated compared to controls (P < 0.05). Overall, these findings suggest that dermal exposure to malathion can reduce reproductive hormone levels and induce cytotoxicity in mice.

Doxorubicin, an anthracycline, is a potent anti-cancer drug; however, its clinical use is hindered by its acute and chronic side effects, particularly cardiotoxicity. This study aimed to assess the protective effects of quercetin on doxorubicin-induced cardiotoxicity. Wistar rats were divided into five groups: a control group receiving saline (1 mL/kg), a quercetin control group receiving DMSO (1 mL/kg), a quercetin group receiving quercetin (20 mg/kg), a doxorubicin group receiving doxorubicin (25 mg/kg) intraperitoneally for three days, and a pretreatment group receiving quercetin (20 mg/kg) for 14 days before being treated with doxorubicin (25 mg/kg). After 14 days, the rats’ weights were recorded, and heart tissue samples were collected for histopathological examination. The results revealed significant weight loss in the doxorubicin-treated animals (P < 0.05), while quercetin pretreatment prevented the weight loss. Pathological analysis showed that quercetin protected the heart tissue from doxorubicin-induced damage. Overall, this study suggests that quercetin pretreatment effectively prevents doxorubicin-induced cardiotoxicity, likely due to its antioxidant properties.

Testicular toxicity is recognized as an underlying factor contributing to male infertility. This study evaluated the protective effects of Artemisia herba-alba against calcium tetrachloride (CCl₄)-induced toxicity in rats, focusing on its impact on ERCC1 gene expression. 20 male Wistar rats were randomly divided into four groups (n = 5 per group). Group I served as the untreated control. Group II received oral CCl₄ (0.4 ml/200g) every other day for three weeks. Group III was administered Artemisia herba-alba (ART) extract orally at 500 mg/kg body weight every other day for three weeks. Group IV was treated with both ART extract (500 mg/kg b.w.) and CCl₄ (0.4 ml/200g) on alternating days over three weeks. Parameters assessed included body weight, relative kidney weight, serum testosterone, tissue oxidative stress markers, ERCC1 gene expression, and testicular histology. The results revealed that CCl₄ exposure led to reduced body weight, lower tissue glutathione (GSH), decreased serum testosterone, elevated lipid peroxidation, upregulated ERCC1 expression, and disrupted testicular histoarchitecture. Conversely, ART co-treatment mitigated these effects, improving testicular histology, downregulating ERCC1 expression, and partially preserving body weight and testosterone levels. Further research with extended treatment periods is recommended to confirm the therapeutic potential of ART in managing testicular toxicity.

This paper presents the findings of multiple investigations into the newly developed Bentorb sorbent, derived from winemaking byproducts, specifically the adhesive residues of yellow blood salt. Elemental analysis revealed that the predominant components of Bentorb include oxygen, carbon, silicon, aluminum, iron, nitrogen, and magnesium, which together make up the majority of the sorbent’s composition. Toxicological assessments of Bentorb were conducted using laboratory animals. To evaluate acute toxicity, 60 white mongrel rats, each weighing approximately 237 ± 7 g, were subjected to the substance. The results showed no significant changes in the general clinical condition of rats in either the experimental or control groups, and all animals survived the tests. Chronic toxicity was assessed in 60 white mice and 40 Wistar rats, each weighing 185 ± 12 g. Over the study period, no notable differences in health or survival rates were observed between the experimental and control groups. The effects of Bentorb on gastrointestinal function were examined in piglets aged 40-80 days. Additionally, the potential embryotoxicity of Bentorb was investigated in pregnant Wistar rats weighing 200-240 g. The study also included analyses of body weight and various internal organs in both control and experimental groups that received Bentorb.

To evaluate patient-derived organoids as a translational testing platform for bio-nano drug delivery systems, this study examined whether organoid assays could predict therapeutic efficacy, identify organ-specific toxicity, and support patient-specific nanomedicine selection. The central objective was to determine whether tumor and matched normal organoids could resolve formulation-dependent differences that are often obscured in conventional two-dimensional cultures. Five bio-nano platforms, comprising lipid nanoparticles, polymeric micelles, gold nanorods, mesoporous silica nanoparticles, and liposomes, were systematically exposed to six patient-derived organoid lines representing colorectal, pancreatic, and lung cancer with matched normal intestinal, pancreatic, and airway organoids. High-content imaging, ATP-based viability testing, cleaved-caspase apoptosis quantification, confocal penetration mapping, epithelial barrier measurements, and cytokine profiling were performed. Organoid drug sensitivity scores were integrated with nanoparticle physicochemical attributes and genomic annotations. The organoid panel discriminated nanocarrier efficacy across tumor types, with targeted lipid nanoparticles and polymeric micelles producing the strongest selective tumor killing. Gold nanorods showed deep penetration but limited drug-release-associated efficacy, whereas mesoporous silica nanoparticles produced mixed efficacy with elevated inflammatory signaling in normal organoids. Personalized benefit-risk ranking identified different optimal nanocarriers for each patient-derived model, demonstrating clinically relevant interpatient heterogeneity. Organoid-based testing provides a scalable and patient-relevant strategy for evaluating bio-nano drug delivery systems before clinical translation. By combining efficacy, toxicity, penetration, and patient-specific sensitivity metrics, this platform may reduce late-stage nanomedicine failure and support individualized therapy selection.